Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)
Inhibikase Therapeutics (IKT) reported Notes Payables of $248911.0 for Q4 2021, up 485.2% year-over-year from $42534.0 in Q4 2020, and little changed quarter-over-quarter from $248911.0 in Q3 2021.
Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021) Analysis & Trends
Inhibikase Therapeutics (IKT) has 2 years of Notes Payables data on file, last reported at $248911.0 in Q4 2021.
- Notes Payables for Q4 2021 came in at $248911.0, up 485.2% year-over-year; the trailing twelve-month figure through Dec 2021 was $248911.0 (up 485.2% YoY), and the FY2021 annual result was $248911.0, up 485.2% from the prior year.
- Notes Payables steadied at $248911.0 in Q4 2021 per IKT's latest filing, from $248911.0 in the prior quarter.
- Over five years, Notes Payables peaked at $994789.0 in Q1 2021 and troughed at $42534.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 248,911.00 |
| Sep 30, 2021 | 248,911.00 |
| Jun 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 994,789.00 |
| Dec 31, 2020 | 42,534.00 |